Project Grant R01CA289381
Award Date
12/5/24
Completion Date
11/30/29
Dollars Obligated
$671K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,192,508 to the Medical University of South Carolina (MUSC) to develop a streamlined antibody capture slide array approach, referred to as the "Glycotyper", to directly profile N-glycans of captured serum glycoproteins. This method combines antibody arrays and imaging mass spectrometry to enable multiplexed N-glycan analysis using only a few microliters of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to support research aimed at understanding the fundamental biological mechanisms underlying intrahepatic cholangiocarcinoma (CCA), a highly desmoplastic and deadly form of bile duct cancer. The primary awardee, the Icahn School of Medicine at Mount Sinai, will receive $1,224,644 over the project period from August 2024 to July 2029. The research seeks to dissect the role...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $518,219 in funding to the University of Pittsburgh to investigate the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a rare and deadly form of liver cancer. The key objectives are to: Elucidate the intertwined roles of the nuclear receptors FXR and CAR in the malignant transformation of hepatocytes into CCA within a cholestatic disease context....
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $563,233.00 to The Medical University of South Carolina (MUSC) to conduct research aimed at overcoming immunosuppression in the tumor microenvironment. The key goals of the project are to: Determine how the sphingosine kinase 2 (SPHK2)-mediated sphingosine-1-phosphate (S1P) signaling axis induces an immunosuppressive phenotype in myeloid-derived suppressor cells (MDSCs). Elucidate the...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
This $483,591.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of California, Davis to develop novel biologic RNA molecules to modulate liver cancer (hepatocellular carcinoma) metabolism. The key research objectives are to: 1) design, clone, express, and purify a focused group of humanized biologic RNA molecules to inhibit liver cancer cell viability; 2) delineate the mechanisms by which these biologic RNAs...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $564,900.00 to Mayo Clinic to support research aimed at "EXPLOITING VIRAL TROPISM TO TARGET CANCER-ASSOCIATED FIBROBLASTS IN INTRAHEPATIC CHOLANGIOCARCINOMA". The award period runs from September 1, 2024 to August 31, 2026. Mayo Clinic, a renowned non-profit academic medical center, will leverage its expertise in cancer biology, drug development,...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Cedars-Sinai Medical Center will investigate the molecular mechanisms by which metabolic dysfunction-associated steatotic liver disease (MASLD) promotes liver metastasis in gastrointestinal cancers. The $646,739 award, effective from April 1, 2025 to March 31, 2030, will focus on the roles of hepatic stellate cells (HSCs) - both intra-tumoral and extra-tumoral - and the effect of...